Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1969 1
1972 1
1979 2
2005 2
2010 2
2011 1
2013 1
2014 2
2015 2
2016 1
2017 3
2018 2
2020 3
2021 3
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

25 results
Results by year
Filters applied: . Clear all
Page 1
Economic burden and health-related quality of life in tenosynovial giant-cell tumour patients in Europe: an observational disease registry.
Lopez-Bastida J, Aranda-Reneo I, Rodríguez-Sánchez B, Peña-Longobardo LM, Ye X, Laeis P, Fronk EM, Palmerini E, Leithner A, Van de Sande MAJ. Lopez-Bastida J, et al. Among authors: fronk em. Orphanet J Rare Dis. 2021 Jul 2;16(1):294. doi: 10.1186/s13023-021-01883-5. Orphanet J Rare Dis. 2021. PMID: 34215312 Free PMC article.
Sex-specific differences in the presentation, clinical course, and quality of life of patients with acute venous thromboembolism according to baseline risk factors. Insights from the PREFER in VTE.
Giustozzi M, Valerio L, Agnelli G, Becattini C, Fronk EM, Klok FA, Konstantinides SV, Vedovati MC, Cohen AT, Barco S. Giustozzi M, et al. Among authors: fronk em. Eur J Intern Med. 2021 Jun;88:43-51. doi: 10.1016/j.ejim.2021.03.014. Epub 2021 Mar 31. Eur J Intern Med. 2021. PMID: 33810940
ETNA-VTE Europe: Benefits and risks of venous thromboembolism treatment using edoxaban in the first 3 months.
Agnelli G, Hoffmann U, Hainaut P, Gaine S, Ay C, Coppens M, Schindewolf M, Jimenez D, Brüggenjürgen B, Levy P, Laeis P, Fronk EM, Zierhut W, Malzer T, Manu MC, Reimitz PE, Bramlage P, Cohen AT; ETNA-VTE-Europe investigators. Agnelli G, et al. Among authors: fronk em. Thromb Res. 2020 Dec;196:297-304. doi: 10.1016/j.thromres.2020.09.001. Epub 2020 Sep 12. Thromb Res. 2020. PMID: 32950897
ETNA VTE Europe: A contemporary snapshot of patients treated with edoxaban in clinical practice across eight European countries.
Cohen AT, Hoffmann U, Hainaut P, Gaine S, Ay C, Coppens M, Schindewolf M, Jimenez D, Brüggenjürgen B, Levy P, Laeis P, Fronk EM, Zierhut W, Malzer T, Manu MC, Reimitz PE, Bramlage P, Agnelli G; ETNA-VTE-Europe investigators. Cohen AT, et al. Among authors: fronk em. Eur J Intern Med. 2020 Dec;82:48-55. doi: 10.1016/j.ejim.2020.08.014. Epub 2020 Aug 18. Eur J Intern Med. 2020. PMID: 32826158
Correction to: Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study.
Cohen AT, Ay C, Hainaut P, Décousus H, Hoffmann U, Gaine S, Coppens M, da Silva PM, Jimenez D, Amann-Vesti B, Brüggenjürgen B, Levy P, Bastida JL, Vicaut E, Laeis P, Fronk EM, Zierhut W, Malzer T, Bramlage P, Agnelli G; ETNA-VTE-Europe investigators. Cohen AT, et al. Among authors: fronk em. Thromb J. 2018 May 31;16:18. doi: 10.1186/s12959-018-0173-5. eCollection 2018. Thromb J. 2018. PMID: 29855634 Free PMC article.
25 results